Table 2 Four algorithms were employed to identify the positive signal of drug-related AEs.

From: A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving pembrolizumab alone and plus lenvatinib

Parameters

ROR

MHRA

BCPNN

MGPS

ALL

Pembrolizumab

63

63

59

162

50

Pembrolizumab + Lenvatinib

43

44

41

120

38

  1. AEs adverse events, ROR reporting odds ratios, MHRA medicines healthcare products regulatory agency, BCPNN Bayesian confidence propagation neural networks, MGPS Multi-item Gamma Poisson Shrinker.
Back to article page